GlaxoSmithKline (GSK) has begun the sale of some of its consumer health brands ... Boutique investment bank Greenhill is to market the products to separate bidders, three anonymous sources ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

Phenylephrine:CVS pulls cold medicines with the ingredient Companies such as Procter & Gamble and GSK were among several accused ... or remove such drugs from the market. The Consumer Healthcare ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

The recent ones are Johnson & Johnson’s spin-off of consumer healthcare business as Kenvue Inc. (KVUE), and GSK’s spin-off ... primarily encompasses products related to Pain and inflammation ...

Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and ...

I attended the NutriChef cooking show and liked it, especially the cleanup of the pans, and I get that their cookware is not as hazardous to health ... Products by NutriChef USA is sold mostly ...

Looking at the sectors faring best as of midday Thursday, shares of Healthcare companies are ... The next best performing sector is the Consumer Products sector, up 0.3%. Among large Consumer ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...